Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.83 |
| ▸ | BCR | P11274 | 13/20 | 0.83 |
| ▸ | KIT | P10721 | 12/20 | 0.83 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.83 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.77 |
| ▸ | ABL2 | P42684 | 3/20 | 0.77 |
| ▸ | EGFR | P00533 | 2/20 | 0.77 |
| ▸ | PLK4 | O00444 | 1/20 | 0.77 |
| ▸ | DDX3X | O00571 | 1/20 | 0.77 |
| ▸ | GAK | O14976 | 1/20 | 0.77 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.77 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.77 |
| ▸ | CA12 | O43570 | 1/20 | 0.77 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | CA1 | P00915 | 1/20 | 0.77 |
| ▸ | CA2 | P00918 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | ALB | P02768 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4411135 | 0.92 | ABL1 (0.79) | ABL1BCRKITLRRK2PDGFRA | |
| SCHEMBL4411137 | 0.92 | ABL1 (0.79) | ABL1BCRKITLRRK2PDGFRA | |
| SCHEMBL29410182 | 0.91 | ABL1 (1.00) | ABL1BCRKITLRRK2PDGFRA | |
| SCHEMBL846536 | 0.91 | ABL1 (1.00) | ABL1BCRKITLRRK2PDGFRA | |
| SCHEMBL31553098 | 0.90 | ABL1 (0.94) | ABL1BCRKITLRRK2PDGFRA | |
| SCHEMBL18210953 | 0.88 | ABL1 (0.83) | ABL1BCRKITLRRK2PDGFRA | |
| SCHEMBL4394539 | 0.88 | ABL1 (0.88) | ABL1BCRKITLRRK2PDGFRA | |
| SCHEMBL4405514 | 0.88 | ABL1 (1.00) | ABL1BCRKITLRRK2PDGFRA | |
| SCHEMBL3058299 | 0.88 | ABL1 (0.86) | ABL1BCRKITLRRK2PDGFRA | |
| SCHEMBL12127861 | 0.88 | ABL1 (0.90) | ABL1BCRKITLRRK2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111329863-A | Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia | 黄泳华 | 2020-06-26 | — | — | CN | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| CN-110559299-A | composition containing pyridyl pyrimidinamine compound and application thereof | 黄泳华 | 2019-12-13 | — | — | CN | claimed |
| CN-110559443-A | composition comprising histamine release-promoting substance and pyridylpyrimidine amine compound, and oral solid preparation containing the same | 黄泳华 | 2019-12-13 | — | — | CN | claimed |
| CN-111329863-A | Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia | 黄泳华 | 2020-06-26 | — | — | CN | disclosed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| CN-110559299-A | composition containing pyridyl pyrimidinamine compound and application thereof | 黄泳华 | 2019-12-13 | — | — | CN | disclosed |
| CN-110559443-A | composition comprising histamine release-promoting substance and pyridylpyrimidine amine compound, and oral solid preparation containing the same | 黄泳华 | 2019-12-13 | — | — | CN | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | ABL1 622/4885BCR 816/4885KIT 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.